Strengths and Limitations of the IMWG 20/2/20 Model in Smoldering Multiple Myeloma

In this segment, Dr. Sagar Lonial asks Dr. Saad Usmani to discuss the clinical utility of the IMWG 20/2/20 model in risk stratification for smoldering multiple myeloma. Dr. Rajkumar explains that one of the key strengths of the model is its simplicity and practicality in routine clinical settings. By incorporating readily available parameters bone marrow plasma cell percentage, serum M-protein level, and the involved-to-uninvolved free light chain ratiothe model allows clinicians to quickly categorize patients into different risk groups and estimate their likelihood of progression to active myeloma. However, Dr. Rajkumar also notes important limitations. While the model is helpful for identifying patients at higher risk, it does not perfectly distinguish those who will progress rapidly from those who may remain stable for longer periods. As a result, clinicians often integrate additional factors, including cytogenetic findings and clinical judgment, when assessing risk in patients with smoldering multiple myeloma.